Statin Use for Secondary Prevention of CVD Remains Suboptimal Statin Use for Secondary Prevention of CVD Remains Suboptimal

Have rates of statin use for secondary prevention improved over the last decade? Do disparities still exist by gender or racial/ethnic groups?Journal of the American Board of Family Medicine
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Related Links:

In conclusion, data revealed no correlation between ex vivo and in vivo studies explained by the collapse of the follicles in ex vivo skin permeation study, leaving only the lipoidal pathway for NE to pass through, thus only NE components, neither nanosizing nor other reported mechanisms, are the main influencing factors. In vivo experiments suggested that o/w NE changed ATOR pathway to follicular delivery leading to accumulation of NE in follicles and consequently a prolonged plasma profile.Graphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
AbstractPurpose of ReviewReduction of serum low-density lipoprotein cholesterol (LDL-C) levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has been shown to significantly reduce cardiovascular events risk. However, fasting and postprandial hypertriglyceridemia as well as reduced high-density lipoprotein cholesterol (HDL-C) remain as residual risk factors of atherosclerotic cardiovascular diseases (ASCVD). To treat patients with hypertriglyceridemia and/or low HDL-C, drugs such as fibrates, nicotinic acids, and n-3 polyunsaturated fatty acids have been used. However, fibrates w...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
Today's research materials are representative of numerous initiatives aiming to produce taxonomies of the biochemistry of aging, to catalog the observed variations. Yet, with the exception of a very small number of unlucky souls bearing rare harmful mutations, we all age for the same underlying reasons. The same processes of metabolism produce the same forms of cell and tissue damage, leading to the same downstream dysfunctions and the same ultimately fatal age-related conditions. Yes, there is some variation in outcome. For all that aging is a universally similar process of multiple interacting forms of damage, some porti...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Publication date: April 2020Source: Biomedicine &Pharmacotherapy, Volume 124Author(s): Napatara Tirawanchai, Kanchana Kengkoom, Duangnate Isarangkul, Jankana Burana-osot, Tapanee Kanjanapruthipong, Surachai Chantip, Panadda Phattanawasin, Uthai Sotanaphun, Sumate AmpawongAbstractKaffir lime leaves and the rhizomes of galangal and lemongrass are the main ingredients in several Thai foods with desirable medicinal effects. Based on their beneficial activities, this study aimed to indicate the chemical properties and in vivo efficacy of a combination of the herbs at a 1:2:1 ratio in a water extract form. Its volatile const...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
High levels of plaque calcification on coronary CT angiography (CCTA) scans...Read more on AuntMinnie.comRelated Reading: CCTA, functional tests stratify heart disease risk by age Onsite FFR-CT tops CCTA in detecting coronary stenosis CCTA reveals statins may lower mortality in low-risk CAD CCTA biomarker may predict mortality from heart disease CCTA biomarker spots high-risk plaques in heart disease
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Authors: Albertson TE, Chenoweth JA, Pearson SJ, Murin S Abstract Introduction: Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is a disease phenotype that shares T helper lymphocyte cell Th1/neutrophilic/non-Type-2 Inflammation pathways thought to be key in COPD and Th2/eosinophilic/Type-2 inflammatory pathways of asthma. The pharmacology of treating ACOS is challenging in severe circumstances.Areas covered: This review evaluates the stepwise treatment of ACOS using pharmacological treatments used in both COPD and asthma. The most common medications involve the same inhalers used to treat COPD...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Pharmacogenomics,Volume 21, Issue 3, Page 163-172, February 2020.
Source: Future Medicine: Pharmacogenomics - Category: Genetics & Stem Cells Authors: Source Type: research
ObjectiveTo explore incidence and progression of coronary atherosclerosis and identify determinants in patients with rheumatoid arthritis (RA). We specifically evaluated the impact of inflammation, cardiac risk factors, duration of medication exposure, and their interactions on coronary plaque progression.MethodsOne hundred one participants with baseline coronary computed tomography angiography findings underwent follow ‐up assessment a mean ± SD of 83 ± 3.6 months after baseline. Plaque burden was reported as the segment involvement score (describing the number of coronary segments with plaque) and the seg...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Original Article Source Type: research
Graves' Orbitopathy (GO) is the most frequent extrathyroidal manifestation of Graves' disease (GD). Its ultimate cause remains unclear, but it is commonly considered an autoimmune disorder due to self recognition of autoantigens constitutively expressed by orbital fibroblasts (OFs), and thyroid epithelial cells. High dose intravenous glucocorticoids (ivGC) are the most commonly used treatment for moderately severe and active GO. However, based on the complex pathogenesis of GO, a number of factors may have a protective and maybe a therapeutic role. The use of other medications improving the effect of GC may increase the ov...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
CONCLUSIONS: The clinical polymorphism effectiveness outlined therein will be assured by diagnostic improvements suitable for driving treatment decisions. In light of our experimental results and literature data, the analysis of the SLCO1B1 T521C variant will allow clinicians to take advantage from a better treatment planned for their patients in order to minimize neuromuscular pain and maximize benefits. PMID: 31957862 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Cholesterol | Health | Primary Care | Statin Therapy